Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 May;146(5):1150–1160.

Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma.

C L Gladson 1, V Pijuan-Thompson 1, M A Olman 1, G Y Gillespie 1, I Z Yacoub 1
PMCID: PMC1869284  PMID: 7747809

Abstract

To understand the role of urokinase (u-PA) and the urokinase receptor (u-PAR) in malignant astrocytoma cell invasion of normal brain, astrocytic expression of u-PAR and u-PA mRNAs were analyzed by riboprobe in situ hybridization in astrocytoma and non-neoplastic brain biopsies. In eight of eight malignant astrocytomas (glioblastomas), u-PAR and u-PA mRNA expression was demonstrated, whereas in seven non-neoplastic brain biopsies, u-PAR and u-PA mRNAs were not expressed. In one of four low grade and all anaplastic astrocytomas u-PAR mRNA was expressed, although u-PA mRNA was undetectable. Consistent with the mRNA detection, u-PAR and u-PA proteins were expressed by malignant astrocytes in five of five glioblastoma biopsies. To study the tumor margin, U-251MG glioblastoma cells were propagated intracerebrally in a severe combined immunodeficient mouse xenograft (28 days), and u-PA mRNA was found to localize predominantly to the leading tumor edge, whereas u-PAR mRNA was expressed throughout the tumor. Furthermore, adherent human U-251MG glioblastoma cells in vitro expressed u-PAR and u-PA proteins, which localized to sites of integrin alpha nu beta 3 cell-matrix contacts. These data indicate that co-expression of u-PAR and u-PA mRNAs and proteins marks the malignant astrocyte phenotype and that u-PA bound to u-PAR may play a role in glioblastoma cell invasion of normal brain by virtue of its expression at the leading tumor edge.

Full text

PDF
1150

Images in this article

1153Figure 1
on p.1153
1154Figure 2
on p.1154
1156Figure 3
on p.1156
1156Figure 4
on p.1156
1157Figure 5
on p.1157

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bigner D. D., Bigner S. H., Pontén J., Westermark B., Mahaley M. S., Ruoslahti E., Herschman H., Eng L. F., Wikstrand C. J. Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol. 1981 May;40(3):201–229. doi: 10.1097/00005072-198105000-00001. [DOI] [PubMed] [Google Scholar]
  2. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993 Feb;15(2):105–111. doi: 10.1002/bies.950150206. [DOI] [PubMed] [Google Scholar]
  3. Boyd D., Florent G., Kim P., Brattain M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res. 1988 Jun 1;48(11):3112–3116. [PubMed] [Google Scholar]
  4. Chen W. T., Olden K., Bernard B. A., Chu F. F. Expression of transformation-associated protease(s) that degrade fibronectin at cell contact sites. J Cell Biol. 1984 Apr;98(4):1546–1555. doi: 10.1083/jcb.98.4.1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cheresh D. A., Spiro R. C. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987 Dec 25;262(36):17703–17711. [PubMed] [Google Scholar]
  6. Crowley C. W., Cohen R. L., Lucas B. K., Liu G., Shuman M. A., Levinson A. D. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5021–5025. doi: 10.1073/pnas.90.11.5021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Danielson P. E., Forss-Petter S., Brow M. A., Calavetta L., Douglass J., Milner R. J., Sutcliffe J. G. p1B15: a cDNA clone of the rat mRNA encoding cyclophilin. DNA. 1988 May;7(4):261–267. doi: 10.1089/dna.1988.7.261. [DOI] [PubMed] [Google Scholar]
  8. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  9. Danø K., Dabelsteen E., Nielsen L. S., Kaltoft K., Wilson E. L., Zeuthen J. Plasminogen activating enzyme in cultured glioblastoma cells. An immunofluorescence study with monoclonal antibody. J Histochem Cytochem. 1982 Nov;30(11):1165–1170. doi: 10.1177/30.11.6183313. [DOI] [PubMed] [Google Scholar]
  10. Estreicher A., Mühlhauser J., Carpentier J. L., Orci L., Vassalli J. D. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990 Aug;111(2):783–792. doi: 10.1083/jcb.111.2.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gladson C. L., Cheresh D. A. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 1991 Dec;88(6):1924–1932. doi: 10.1172/JCI115516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gladson C. L., Schleef R. R., Binder B. R., Loskutoff D. J., Griffin J. H. A comparison between activated protein C and des-1-41-light chain-activated protein C in reactions with type 1 plasminogen activator inhibitor. Blood. 1989 Jul;74(1):173–181. [PubMed] [Google Scholar]
  13. Gladson C. L., Wilcox J. N., Sanders L., Gillespie G. Y., Cheresh D. A. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors. J Cell Sci. 1995 Mar;108(Pt 3):947–956. doi: 10.1242/jcs.108.3.947. [DOI] [PubMed] [Google Scholar]
  14. Haddock R. C., Spell M. L., Baker C. D., 3rd, Grammer J. R., Parks J. M., Speidel M., Booyse F. M. Urokinase binding and receptor identification in cultured endothelial cells. J Biol Chem. 1991 Nov 15;266(32):21466–21473. [PubMed] [Google Scholar]
  15. Hahn J. S., Bejar R., Gladson C. L. Neonatal subependymal giant cell astrocytoma associated with tuberous sclerosis: MRI, CT, and ultrasound correlation. Neurology. 1991 Jan;41(1):124–128. doi: 10.1212/wnl.41.1.124. [DOI] [PubMed] [Google Scholar]
  16. Hall S. W., VandenBerg S. R., Gonias S. L. Expression of plasminogen receptors on C6 glioma cells. Brain Res. 1989 Aug 28;495(2):373–376. doi: 10.1016/0006-8993(89)90231-x. [DOI] [PubMed] [Google Scholar]
  17. Hollas W., Blasi F., Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res. 1991 Jul 15;51(14):3690–3695. [PubMed] [Google Scholar]
  18. Kasai S., Arimura H., Nishida M., Suyama T. Primary structure of single-chain pro-urokinase. J Biol Chem. 1985 Oct 5;260(22):12382–12389. [PubMed] [Google Scholar]
  19. Keohane M. E., Hall S. W., VandenBerg S. R., Gonias S. L. Secretion of alpha 2-macroglobulin, alpha 2-antiplasmin, and plasminogen activator inhibitor-1 by glioblastoma multiforme in primary organ culture. J Neurosurg. 1990 Aug;73(2):234–241. doi: 10.3171/jns.1990.73.2.0234. [DOI] [PubMed] [Google Scholar]
  20. Kingsley P. D., Angerer L. M., Angerer R. C. Major temporal and spatial patterns of gene expression during differentiation of the sea urchin embryo. Dev Biol. 1993 Jan;155(1):216–234. doi: 10.1006/dbio.1993.1020. [DOI] [PubMed] [Google Scholar]
  21. Kleihues P., Burger P. C., Scheithauer B. W. The new WHO classification of brain tumours. Brain Pathol. 1993 Jul;3(3):255–268. doi: 10.1111/j.1750-3639.1993.tb00752.x. [DOI] [PubMed] [Google Scholar]
  22. Kohga S., Harvey S. R., Weaver R. M., Markus G. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res. 1985 Apr;45(4):1787–1796. [PubMed] [Google Scholar]
  23. Kono S., Rao J. S., Bruner J. M., Sawaya R. Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors. J Neuropathol Exp Neurol. 1994 May;53(3):256–262. doi: 10.1097/00005072-199405000-00006. [DOI] [PubMed] [Google Scholar]
  24. Landau B. J., Kwaan H. C., Verrusio E. N., Brem S. S. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res. 1994 Feb 15;54(4):1105–1108. [PubMed] [Google Scholar]
  25. Lang I. M., Marsh J. J., Konopka R. G., Olman M. A., Binder B. R., Moser K. M., Schleef R. R. Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation. 1993 Jun;87(6):1990–2000. doi: 10.1161/01.cir.87.6.1990. [DOI] [PubMed] [Google Scholar]
  26. Lang I. M., Marsh J. J., Olman M. A., Moser K. M., Loskutoff D. J., Schleef R. R. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation. 1994 Jun;89(6):2715–2721. doi: 10.1161/01.cir.89.6.2715. [DOI] [PubMed] [Google Scholar]
  27. Liotta L. A., Rao C. N., Wewer U. M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem. 1986;55:1037–1057. doi: 10.1146/annurev.bi.55.070186.005133. [DOI] [PubMed] [Google Scholar]
  28. Lund L. R., Rømer J., Rønne E., Ellis V., Blasi F., Danø K. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J. 1991 Nov;10(11):3399–3407. doi: 10.1002/j.1460-2075.1991.tb04904.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mackay A. R., Corbitt R. H., Hartzler J. L., Thorgeirsson U. P. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res. 1990 Sep 15;50(18):5997–6001. [PubMed] [Google Scholar]
  30. Martuza R. L., Malick A., Markert J. M., Ruffner K. L., Coen D. M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991 May 10;252(5007):854–856. doi: 10.1126/science.1851332. [DOI] [PubMed] [Google Scholar]
  31. Melton D. A., Krieg P. A., Rebagliati M. R., Maniatis T., Zinn K., Green M. R. Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res. 1984 Sep 25;12(18):7035–7056. doi: 10.1093/nar/12.18.7035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Mohanam S., Sawaya R., McCutcheon I., Ali-Osman F., Boyd D., Rao J. S. Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody. Cancer Res. 1993 Sep 15;53(18):4143–4147. [PubMed] [Google Scholar]
  33. Nagai M., Hiramatsu R., Kanéda T., Hayasuke N., Arimura H., Nishida M., Suyama T. Molecular cloning of cDNA coding for human preprourokinase. Gene. 1985;36(1-2):183–188. doi: 10.1016/0378-1119(85)90084-8. [DOI] [PubMed] [Google Scholar]
  34. Nakajima K., Tsuzaki N., Shimojo M., Hamanoue M., Kohsaka S. Microglia isolated from rat brain secrete a urokinase-type plasminogen activator. Brain Res. 1992 Apr 17;577(2):285–292. doi: 10.1016/0006-8993(92)90285-h. [DOI] [PubMed] [Google Scholar]
  35. Newman P. J., Kahn R. A., Hines A. Detection and characterization of monoclonal antibodies to platelet membrane proteins. J Cell Biol. 1981 Jul;90(1):249–253. doi: 10.1083/jcb.90.1.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Nielsen L. S., Hansen J. G., Skriver L., Wilson E. L., Kaltoft K., Zeuthen J., Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry. 1982 Dec 7;21(25):6410–6415. doi: 10.1021/bi00268a014. [DOI] [PubMed] [Google Scholar]
  37. Olman M. A., Marsh J. J., Lang I. M., Moser K. M., Binder B. R., Schleef R. R. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation. 1992 Oct;86(4):1241–1248. doi: 10.1161/01.cir.86.4.1241. [DOI] [PubMed] [Google Scholar]
  38. Ossowski L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol. 1988 Dec;107(6 Pt 1):2437–2445. doi: 10.1083/jcb.107.6.2437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Paganetti P. A., Caroni P., Schwab M. E. Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloprotease. J Cell Biol. 1988 Dec;107(6 Pt 1):2281–2291. doi: 10.1083/jcb.107.6.2281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Pyke C., Kristensen P., Ralfkiaer E., Grøndahl-Hansen J., Eriksen J., Blasi F., Danø K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol. 1991 May;138(5):1059–1067. [PMC free article] [PubMed] [Google Scholar]
  41. Rao J. S., Baker J. B., Morantz R. A., Kimler B., Evans R., Festoff B. W. Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin. Cancer Res. 1990 Aug 15;50(16):5039–5044. [PubMed] [Google Scholar]
  42. Rehemtulla A., Murphy P., Dobson M., Hart D. A. Purification and partial characterization of a plasminogen activator inhibitor from the human glioblastoma, U138. Biochem Cell Biol. 1988 Dec;66(12):1270–1277. doi: 10.1139/o88-147. [DOI] [PubMed] [Google Scholar]
  43. Riccio A., Grimaldi G., Verde P., Sebastio G., Boast S., Blasi F. The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res. 1985 Apr 25;13(8):2759–2771. doi: 10.1093/nar/13.8.2759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Roldan A. L., Cubellis M. V., Masucci M. T., Behrendt N., Lund L. R., Danø K., Appella E., Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J. 1990 Feb;9(2):467–474. doi: 10.1002/j.1460-2075.1990.tb08132.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Sakata Y., Loskutoff D. J., Gladson C. L., Hekman C. M., Griffin J. H. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood. 1986 Dec;68(6):1218–1223. [PubMed] [Google Scholar]
  46. Sappino A. P., Madani R., Huarte J., Belin D., Kiss J. Z., Wohlwend A., Vassalli J. D. Extracellular proteolysis in the adult murine brain. J Clin Invest. 1993 Aug;92(2):679–685. doi: 10.1172/JCI116637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Schlechte W., Murano G., Boyd D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res. 1989 Nov 1;49(21):6064–6069. [PubMed] [Google Scholar]
  48. Sitrin R. G., Gyetko M. R., Kole K. L., McKeever P., Varani J. Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines. Cancer Res. 1990 Aug 15;50(16):4957–4961. [PubMed] [Google Scholar]
  49. Skriver L., Larsson L. I., Kielberg V., Nielsen L. S., Andresen P. B., Kristensen P., Danø K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol. 1984 Aug;99(2):753–757. doi: 10.1083/jcb.99.2.753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Stahl A., Mueller B. M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 1994 Jun 1;54(11):3066–3071. [PubMed] [Google Scholar]
  51. Vassalli J. D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985 Jan;100(1):86–92. doi: 10.1083/jcb.100.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Verde P., Stoppelli M. P., Galeffi P., Di Nocera P., Blasi F. Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4727–4731. doi: 10.1073/pnas.81.15.4727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Wayner E. A., Orlando R. A., Cheresh D. A. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol. 1991 May;113(4):919–929. doi: 10.1083/jcb.113.4.919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wilcox J. N., Smith K. M., Williams L. T., Schwartz S. M., Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest. 1988 Sep;82(3):1134–1143. doi: 10.1172/JCI113671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Wolf B. B., Vasudevan J., Henkin J., Gonias S. L. Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator. J Biol Chem. 1993 Aug 5;268(22):16327–16331. [PubMed] [Google Scholar]
  56. Yamamoto M., Sawaya R., Mohanam S., Bindal A. K., Bruner J. M., Oka K., Rao V. H., Tomonaga M., Nicolson G. L., Rao J. S. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res. 1994 Jul 15;54(14):3656–3661. [PubMed] [Google Scholar]
  57. Yatohgo T., Izumi M., Kashiwagi H., Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct Funct. 1988 Aug;13(4):281–292. doi: 10.1247/csf.13.281. [DOI] [PubMed] [Google Scholar]
  58. de Vries T. J., Quax P. H., Denijn M., Verrijp K. N., Verheijen J. H., Verspaget H. W., Weidle U. H., Ruiter D. J., van Muijen G. N. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol. 1994 Jan;144(1):70–81. [PMC free article] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES